Acute kidney transplant rejection
transplant rejection · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Immune-mediated graft injury (T-cell-mediated and/or antibody-mediated) presenting as rising creatinine, often with proteinuria or reduced output. Biopsy-directed treatment with steroids, antithymocyte globulin or antibody-directed therapy is needed to salvage the graft.
Red flags
- Rapidly rising creatinine with oliguria
- Graft tenderness, fever or pain
- Strong/rising donor-specific antibodies
- Vascular (Banff) rejection on biopsy
- No response to pulsed steroids (steroid-resistant rejection)
Assessment
Differential diagnosis
- T-cell-mediated rejection
- Antibody-mediated rejection
- Calcineurin inhibitor nephrotoxicity
- BK virus nephropathy
- Obstruction/urine leak or vascular complication
- Dehydration/pre-renal or recurrent GN
Investigations
- Creatinine/eGFR trend and urinalysis/ACR
- Tacrolimus/ciclosporin level (exclude toxicity)
- Donor-specific antibodies (DSA)
- Transplant Doppler ultrasound (exclude obstruction/vascular cause)
- BK and CMV viral loads
- Transplant biopsy with Banff grading (definitive) and C4d staining
Management
- Investigate any unexplained creatinine rise urgently; exclude pre-renal, obstruction, CNI toxicity and infection first
- Check CNI levels, DSA and viral loads; arrange Doppler ultrasound
- Obtain a transplant biopsy to confirm and classify rejection (Banff) before definitive therapy
- Treat T-cell-mediated rejection with pulsed IV methylprednisolone
- Use antithymocyte globulin for steroid-resistant or severe (vascular) T-cell-mediated rejection
- Treat antibody-mediated rejection with plasma exchange plus IVIG, +/- rituximab, per centre protocol
- Optimise and ensure adequate baseline immunosuppression; address non-adherence
- Give/continue infection prophylaxis given intensified immunosuppression
- Monitor graft function response and consider repeat biopsy if no improvement
- Manage complications of treatment (infection, cytokine reactions with ATG)
- Plan long-term immunosuppression adjustment and DSA monitoring
- Prepare for return to dialysis/relisting if the graft is not salvageable
Drugs & doses
Methylprednisolone 250-500 mg IV daily for 3-5 days (T-cell-mediated rejection)
Anti-thymocyte globulin 1.5 mg/kg/day IV for 5-7 days (steroid-resistant/severe rejection)
IVIG 1-2 g/kg total divided, with plasma exchange (antibody-mediated rejection)
Rituximab 375 mg/m2 IV (selected antibody-mediated rejection)
Prophylaxis: co-trimoxazole 480 mg PO daily and valganciclovir 900 mg PO daily (renally dosed) during intensified immunosuppression
Disposition
Admit under transplant nephrology; urgent biopsy and treatment at the transplant centre. Close monitoring; involve histopathology and HLA lab.
Complications & pitfalls
- Graft loss and return to dialysis
- Infection from intensified immunosuppression
- Chronic rejection/transplant glomerulopathy
- Cytokine-release reactions (ATG)
- Sensitisation complicating re-transplantation
- Post-transplant lymphoproliferative disorder
Exam pearls
- Biopsy before treating — distinguish rejection from CNI toxicity and BK nephropathy
- Antibody-mediated rejection needs DSA testing and C4d, not just steroids
- Check adherence and drug levels in every rejection episode
- Intensified immunosuppression demands reinstated infection prophylaxis
- Early recognition and treatment is key to graft salvage
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.